Andrea J. Gonzales

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib

Jeffrey A. Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale et al. · Cancer Research · 2007 · 718 citations · Full text

Medicine, Oncology, Pharmacology +13

Oclacitinib (<scp>APOQUEL</scp>^®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy

Andrea J. Gonzales, Jill Bowman, Gregory J. Fici et al. · Journal of Veterinary Pharmacology and Therapeutics · 2014 · 245 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

Andrea J. Gonzales, Kenneth E. Hook, Irene W. Althaus et al. · Molecular Cancer Therapeutics · 2008 · 221 citations · Full text

Medicine, Oncology, Pharmacology +15

Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E.

Irene W. Althaus, James J. Chou, Andrea J. Gonzales et al. · Journal of Biological Chemistry · 1993 · 164 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

The quinoline U-78036 is a potent inhibitor of HIV-1 reverse transcriptase

Irene W. Althaus, Andrea J. Gonzales, James J. Chou et al. · Journal of Biological Chemistry · 1993 · 162 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17